Neural Circuit Effects of Ketamine in Depression

This interventional trial (n=120) aims to explore the neural circuit-specific mechanisms of ketamine’s effect on anhedonia and anxiety in individuals with major depressive disorder (MDD).

Conducted by the Icahn School of Medicine at Mount Sinai, the study investigates the acute and sustained effects of ketamine on sgACC activation and depression symptoms using ultra-high field 7-Tesla MRI.

Participants, aged 18 to 65, diagnosed with MDD according to DSM-5 criteria, will be recruited. They will receive either ketamine or a placebo infusion.

The primary outcome measure is sgACC response to the Incentive Flanker Task, with secondary measures assessing treatment-related changes in sgACC response.

The study started on January 31, 2024, and is expected to conclude by April 30, 2028.

Topic Depression Anxiety
Compound Placebo Ketamine
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Icahn School of Medicine at Mount Sinai
This company doesn't have a full profile yet, it is linked to a clinical trial.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.